Cti BioPharma (NASDAQ: CTIC)
Some price data may be temporarily unavailable.
Cti BioPharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cti BioPharma Company Info
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
News & Analysis
Why Shares of CTI BioPharma Are Soaring Wednesday
A buyout offer from Swedish Orphan Biovitrum drove up the stock's price.
Why CTI BioPharma Stock Crushed the Market Today
Simultaneous double thumbs-ups from a pair of pundits gave it boost.
Why CTI BioPharma Stock Withered on Wednesday
Investors didn't exactly cheer the latest prognosticator move on the company's shares.
Why CTI BioPharma Stock Got Rocked on Tuesday
Woe betide any company that reports even a narrow bottom-line miss on quarterly results these days.
Why CTI BioPharma Stock Blasted 18% Higher Today
An analyst launches coverage of the company with an unequivocal buy recommendation.
Why CTI Biopharma Stock Is Surging Today
A strong launch for the company's first commercialized drug drew a cheer from investors.
Why CTI BioPharma Stock Is Plunging Today
The FDA extended its review period for myelofibrosis candidate pacritinib.
Why CTI BioPharma Corp. Crashed Today
The FDA's requirement of a new late-stage clinical study caused the biotech stock to plunge.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.